Breaking News
March 22, 2019 - Less invasive valve replacement can be safe and effective alternative for healthier patients
March 22, 2019 - Aphasia research reveals new, complex interactions between thought and language
March 22, 2019 - Artificial neural networks can predict how different areas in the brain respond to words
March 22, 2019 - Age-related changes to gut microbiome have adverse impact on vascular health, study shows
March 22, 2019 - Isolated seniors chat online to prevent cognitive decline
March 22, 2019 - Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
March 22, 2019 - Eruptive xanthomatosis
March 22, 2019 - Cause of vascular disease in kidney failure reversed in animal model
March 22, 2019 - Researchers discover possible new therapeutic strategy for pancreatic cancer
March 22, 2019 - Ebola spreads to second largest city in DRC
March 22, 2019 - Perivascular spaces contribute to worse cognitive health in older adults
March 22, 2019 - Adolescent daily users more likely to obtain electronic cigarettes from commercial sources
March 22, 2019 - FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
March 22, 2019 - Diabetes myths and facts: MedlinePlus Medical Encyclopedia
March 22, 2019 - TGen and ABL pursue global rollout of advanced TB test
March 22, 2019 - Traffic light labels influence people to choose healthier and more sustainable meals
March 22, 2019 - Alzheimer’s patients using antiepileptic drugs have twice the risk of pneumonia, study shows
March 22, 2019 - Skin diseases may be more prevalent than previously thought
March 22, 2019 - Overall rates of death from breast cancer are falling across the EU
March 22, 2019 - Novel plasmid could hold key to control of mosquito-borne illness
March 22, 2019 - Female Emergency Physicians Paid Less Than Males
March 22, 2019 - Estimated average glucose (eAG): MedlinePlus Medical Encyclopedia
March 22, 2019 - Experimental drug could be new option for type 2 diabetes
March 22, 2019 - Five Things To Know About The Electronic Health Records Mess
March 22, 2019 - TMJ disorders could be treated with tissue-engineered implants after successful animal study
March 22, 2019 - Team-based approach is key to successful care of pregnant women with heart failure
March 22, 2019 - Study identifies gene variant associated with accelerated cellular aging
March 21, 2019 - Salk scientists show how background noise from neurons can interrupt focused attention
March 21, 2019 - New class of drugs could help treat patients diagnosed with ovarian cancer
March 21, 2019 - Tecentriq Approved for Small Cell Lung Cancer
March 21, 2019 - Adipocyte glucocorticoid receptors play a role in developing steroid diabetes
March 21, 2019 - Climate change can affect nutrient content of crops, harming human health
March 21, 2019 - Podcast: KHN’s ‘What The Health’ Surprise! Fixing Surprise Medical Bills Is Harder Than it Looks
March 21, 2019 - Chemistry researchers patent new method for making anti-leukemia compounds
March 21, 2019 - UIC scientists identify hidden proteins in bacteria
March 21, 2019 - New Australian drug trial achieves remarkable results in patients with acute myeloid leukemia
March 21, 2019 - Females live longer when they have help raising offspring
March 21, 2019 - How did orthodontists sell orthodontics?
March 21, 2019 - In the Spotlight: From dietitian to physician assistant student
March 21, 2019 - The CRISPR Revolution: What You Need to Know
March 21, 2019 - FDA Chief Calls For Stricter Scrutiny Of Electronic Health Records
March 21, 2019 - Combined glucocorticoid and antioxidant therapy could benefit premature babies
March 21, 2019 - Low levels of certain eye proteins could serve as predictor for Alzheimer’s
March 21, 2019 - Post-traumatic holocaust survivors transmit negative views on aging to offspring
March 21, 2019 - City of Hope receives $7.5 million in grant awards to study cutaneous T cell lymphoma
March 21, 2019 - New video game-led training device helps stroke survivors regain arm mobility
March 21, 2019 - Compounds in coffee could slow prostate cancer growth
March 21, 2019 - New mobile DNA element in Wolbachia may contribute to improved disease control strategies
March 21, 2019 - Phase 2 Clinical Trial of Bermekimab Shows Potential New Standard of Care for Treatment of Hidradenitis Suppurativa, Including Significant Pain Reduction without Antibiotics
March 21, 2019 - More than one-third of patients risk major bleeding by doubling up on blood thinners
March 21, 2019 - A skeptical look at popular diets: Thumbs up for Mediterranean
March 21, 2019 - PTSD After Cardiac Arrest Predicts More Heart Trouble
March 21, 2019 - Role of immunological imprinting in elicitation of new antibodies
March 21, 2019 - Breast cancer relapse predictor tool may soon be a reality
March 21, 2019 - New computer program developed by TGen lights up cancer-causing genetic mutations
March 21, 2019 - FDA warns two breast implant makers for failure to comply with post-approval study requirements
March 21, 2019 - Butler Hospital receives COBRE grant to enhance research on neuropsychiatric illnesses
March 21, 2019 - Majority of osteoporosis clinical practice guidelines ignore patients’ voices
March 21, 2019 - Generic messages don’t help patients to lose weight
March 21, 2019 - Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
March 21, 2019 - Two-drug combos using popular calcium channel blocker show superiority in lowering BP
March 21, 2019 - Q BioMed and Mannin Research collaborate with McMaster University to develop GDF15 biomarker glaucoma diagnostic kit
March 21, 2019 - First-in-human pilot study shows positive results for ‘bacteria-phobic’ catheter
March 21, 2019 - Itamar Medical launches next-generation WatchPAT system for home sleep apnea testing
March 21, 2019 - Study estimates health and economic impacts of healthy food prescriptions
March 21, 2019 - Detecting fungal disease in crops with multispectral imaging system
March 21, 2019 - MIT announces creation of the Alana Down Syndrome Center
March 21, 2019 - Next-generation LVAD device clinically superior, safer for heart failure patients
March 21, 2019 - Allergan Announces FDA Approval of Avycaz (ceftazidime and avibactam) for Pediatric Patients
March 21, 2019 - Mutations in noncoding genes could play big role in regulating cancer, study finds
March 21, 2019 - A medical student’s thoughts on Match Day
March 21, 2019 - Are eggs good or bad for you?
March 21, 2019 - New analysis reveals precision oncology insights for colorectal cancer
March 21, 2019 - Pollutants appear to weaken immune system and increase pathogen virulence
March 21, 2019 - Researchers develop and validate scale for rating severity of mononucleosis
March 21, 2019 - Scientists identify generation of key immune response in mice on introducing solid food
March 21, 2019 - New nanomaterial could restore internal structure of damaged bones
March 21, 2019 - Selective destruction of prostate tumor as effective as complete prostate removal
March 21, 2019 - 2011 to 2015 Saw Increase in Psychiatric ED Visits for Youth
March 21, 2019 - Tapeworm drug targets common vulnerability in tumor cells
Study highlights accuracy of DecisionDx-Melanoma prognostic test in patients with Stage II-IIIA melanoma

Study highlights accuracy of DecisionDx-Melanoma prognostic test in patients with Stage II-IIIA melanoma

image_pdfDownload PDFimage_print

Castle Biosciences, Inc., the skin cancer diagnostics company providing molecular diagnostics to improve cancer management decisions, today announced the presentation of data highlighting how the accuracy of the DecisionDx®-Melanoma gene expression profile (GEP) test in patients with Stage II and IIIA melanoma can improve adjuvant clinical trial design at the 2018 Society for Melanoma Research International Congress held in Manchester, England from October 24-27.

The study titled, “Implications of a 31-gene expression profile test for cutaneous melanoma on AJCC-based risk assessment and adjuvant therapy trial design,” was presented as a poster at the meeting.

Study Background

  • The adjuvant treatment setting for melanoma has experienced significant advances in recent years. While therapies provide clear benefits for a subset of melanoma patients, they also can be associated with significant adverse effects. Accurate assessment of individual patient risk is increasingly important to guide treatment decisions, especially for those with no evidence of disease.
  • The analysis focused on the use of the DecisionDx-Melanoma test to inform which Stage II and IIIA melanoma patients are at high risk of recurrence and could benefit from adjuvant therapy. Adjuvant therapy trials are being considered or underway for Stage II and Stage IIIA patients, but recurrence rates in this population make trials in this population challenging.
  • The study assessed whether the DecisionDx-Melanoma test could have a role in patient selection for future adjuvant therapy clinical trials, and evaluated the potential cost savings associated with patient enrollment based on risk assessment.

Study Details and Key Findings

  • The DecisionDx-Melanoma test was previously validated in a cohort of 690 patients from 18 centers to accurately predict 5-year risk of recurrence for patients with melanoma (Class 1A lowest risk; Class 2B highest risk).
  • This analysis included a subset of 173 patients who had Stage II or IIIA melanoma (restaged using American Joint Committee on Cancer [AJCC] 8th edition).
  • Patients in the Stage II-IIIA cohort who had a Class 1A DecisionDx-Melanoma test result had a 5-year melanoma-specific survival (MSS) rate of 100%, similar to the risk of patients with Stage 1A melanoma. Stage II-IIIA patients who had a Class 2B result had an MSS of 85%, similar to a Stage IIIB risk.
  • Similarly, 5-year recurrence-free survival for patients in the Stage II-IIIA cohort who had a Class 2B DecisionDx-Melanoma test result was 39% and distant metastasis-free survival was 54%, significantly lower than those for patients with a Class 1A result.
  • Study results showed that using the DecisionDx-Melanoma test to select patients for a clinical trial, sample size could be reduced by 36% with an overall reduction in trial costs if enrollment focused on patients with a high risk of recurrence as determined by a DecisionDx-Melanoma Class 2B result.

“Optimization of adjuvant clinical trial enrollment for melanoma is increasingly important given the adverse effects that are associated with current targeted and immune checkpoint therapies,” said Sancy Leachman M.D., Ph.D., Professor and chair, Department of Dermatology and Director, Melanoma Research Program, Oregon Health & Science University. “These data support application of the DecisionDx-Melanoma test to identify Stage II-IIIA patients who are at higher risk for recurrence and metastasis and are therefore appropriate candidates for adjuvant therapy consideration in a clinical trial.”

Source:

Posted in: Drug Trial News | Medical Condition News

Tags: Adjuvant Therapy, Cancer, Carcinoma, Cell, Clinical Trial, Dermatology, Diagnostics, Gene, Gene Expression, Genes, Laboratory, Lymph Node, Melanoma, Metastasis, Molecular Diagnostics, pH, Research, Skin, Skin Cancer, Tumor

Tagged with:

About author

Related Articles